1. [CASE 1 — QUESTION 1]
An 81-year-old woman with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD, estimated glomerular filtration rate [eGFR] 27 mL/min/1.73m2) has taken glyburide for years. During a febrile viral illness she eats almost nothing for two days and is brought to the emergency department with a blood glucose of 34 mg/dL. After an ampule of intravenous (IV) dextrose she improves, but becomes hypoglycemic again within three hours. Which combination of factors best explains the recurrent, prolonged hypoglycemia?
A) Glyburide is rapidly cleared, so the recurrence must reflect a coexisting insulinoma
B) Glyburide's weakly active metabolites accumulate as renal function declines, and because sulfonylurea-induced insulin secretion is glucose-independent, insulin release continues even as glucose normalizes
C) Glyburide suppresses hepatic gluconeogenesis, removing the liver's ability to correct low glucose
D) The febrile illness has induced CYP2C9, increasing conversion of glyburide to a more potent metabolite
E) Renal impairment accelerates glyburide elimination, so the recurrence is unrelated to the drug
ANSWER: B
Rationale:
Glyburide is metabolized to weakly active metabolites that accumulate as renal function declines, and sulfonylurea-induced insulin secretion is glucose-independent, so insulin release continues even after glucose is corrected, producing recurrent and prolonged hypoglycemia.
Option A: Option A is incorrect because glyburide and its metabolites are not rapidly cleared in CKD; an insulinoma need not be invoked to explain the recurrence.
Option C: Option C is incorrect because glyburide is a secretagogue and does not lower glucose by suppressing hepatic gluconeogenesis.
Option D: Option D is incorrect because the recurrence is explained by metabolite accumulation and glucose-independent secretion, not by induction of CYP2C9 generating a more potent metabolite.
Option E: Option E inverts the renal effect: impairment causes accumulation and prolonged action rather than accelerated elimination.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. After the second hypoglycemic episode, the team must decide on disposition. What is the most appropriate management?
A) Discharge home with instructions to eat regularly, since the glucose has corrected twice
B) Give oral glucose gel and observe for one hour, then discharge
C) Administer glucagon and discharge once she tolerates oral intake
D) Admit for continuous IV dextrose infusion and observation until the glyburide and its active metabolites have cleared
E) Resume the home glyburide dose immediately to maintain glycemic stability
ANSWER: D
Rationale:
Because glyburide-induced hypoglycemia in CKD is prolonged and recurrent, the patient requires admission for continuous IV dextrose infusion and observation until the drug and its active metabolites have cleared.
Option A: Option A is incorrect because transient correction does not signal resolution; recurrence is expected.
Option B: Option B is incorrect because a one-hour observation underestimates the prolonged duration of glyburide-induced hypoglycemia in renal impairment.
Option C: Option C is incorrect because glucagon produces only brief hepatic glucose release and does not stop ongoing insulin secretion, so discharge would be unsafe.
Option E: Option E is incorrect because resuming glyburide would perpetuate the glucose-independent insulin secretion driving the hypoglycemia.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. After recovery, the team plans her outpatient regimen. If a sulfonylurea is still to be used, which agent is the safest choice in her CKD, and why?
A) Glipizide, because it is metabolized by CYP2C9 to inactive metabolites that do not accumulate in renal impairment, reducing the risk of prolonged hypoglycemia
B) Glyburide at a lower dose, because dose reduction eliminates the metabolite accumulation problem
C) Chlorpropamide, because its long half-life provides smoother control in older adults
D) Tolbutamide, because first-generation agents are cleared independently of renal function
E) Glimepiride, because it is excreted entirely unchanged in the urine and therefore cannot accumulate
ANSWER: A
Rationale:
Glipizide is metabolized by CYP2C9 to inactive metabolites that do not accumulate as renal function declines, making it the safest sulfonylurea in CKD when a secretagogue is required.
Option B: Option B is incorrect because glyburide's active metabolites still accumulate in renal impairment even at reduced dose, so it remains hazardous.
Option C: Option C is incorrect because chlorpropamide's long half-life increases hypoglycemia risk and is not preferred in renal impairment.
Option D: Option D is incorrect because first-generation agents such as tolbutamide are not cleared independently of renal function and have unfavorable profiles.
Option E: Option E is incorrect because glimepiride is hepatically metabolized to an active M1 metabolite that is renally excreted, so it is not excreted unchanged and does require dose reduction in CKD.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Stepping back from the choice of sulfonylurea, the team considers whether a secretagogue is the best long-term class for her at all, given her CKD and hypoglycemia history. Which statement best reflects current guideline-based reasoning?
A) A sulfonylurea is the preferred long-term agent because it is the only inexpensive option for CKD
B) Insulin secretagogues are the safest class in CKD because they do not depend on renal clearance
C) Secretagogues are not preferred on the kidney axis; given her CKD and hypoglycemia risk, the team should reassess the overall regimen, considering an SGLT-2 (sodium-glucose cotransporter-2) inhibitor for cardiorenal protection and metformin if her eGFR permits, rather than defaulting to a secretagogue
D) Meglitinides should replace the sulfonylurea because they provide cardiorenal protection in CKD
E) No change is needed because hypoglycemia from one agent does not affect long-term class selection
ANSWER: C
Rationale:
Within the comorbidity-axis framework, secretagogues are not preferred on the kidney axis; given her CKD and demonstrated hypoglycemia risk, the appropriate reasoning is to reassess the regimen, favoring an SGLT-2 inhibitor for cardiorenal protection and metformin if her eGFR permits, rather than defaulting to a secretagogue.
Option A: Option A is incorrect because low cost does not make a sulfonylurea the preferred long-term agent in a patient with CKD and hypoglycemia risk.
Option B: Option B is incorrect because secretagogues are not the safest class in CKD; sulfonylurea metabolites accumulate and prolong hypoglycemia.
Option D: Option D is incorrect because meglitinides do not provide cardiorenal protection.
Option E: Option E is incorrect because a serious hypoglycemia event, particularly in CKD, should prompt reconsideration of long-term class selection.
5. [CASE 2 — QUESTION 1]
A 66-year-old man with T2DM on metformin (eGFR 47 mL/min/1.73m2) is scheduled for a contrast-enhanced CT using iodinated contrast to evaluate abdominal pain. The team must decide how to manage his metformin around the procedure. What is the most appropriate plan?
A) Continue metformin without interruption, since its hepatic metabolism is unaffected by contrast
B) Permanently discontinue metformin, since contrast is a lifelong contraindication to the drug
C) Increase the metformin dose before the scan to maintain glycemic control during the procedure
D) Switch to glyburide for the periprocedural period, since sulfonylureas are safer than metformin during contrast exposure
E) Hold metformin at the time of the procedure and withhold it for 48 hours pending a recheck of renal function before restarting
ANSWER: E
Rationale:
Metformin is cleared entirely by the kidney, and iodinated contrast can precipitate acute kidney injury that lowers the eGFR into the contraindicated range while metformin accumulates; the correct plan is to hold metformin at the time of the procedure and withhold it for 48 hours pending a renal recheck before restarting.
Option A: Option A is incorrect because metformin is renally cleared, not hepatically metabolized, so contrast is highly relevant.
Option B: Option B is incorrect because the hold is temporary, not a permanent contraindication.
Option C: Option C is incorrect because increasing the dose before a potential renal insult worsens the accumulation risk.
Option D: Option D is incorrect because glyburide is hazardous with any acute renal decline due to metabolite accumulation and is not a safer substitute.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. Suppose the metformin had not been held and the patient developed contrast-induced acute kidney injury. By what mechanism would this combination raise his risk of metformin-associated lactic acidosis?
A) Metformin is not metabolized and is cleared entirely by the kidney, so acute kidney injury causes drug and lactate accumulation, since metformin also impairs hepatic and renal lactate clearance through complex I inhibition
B) Metformin is hepatically metabolized to a lactic acid metabolite that the injured kidney cannot excrete
C) Acute kidney injury induces hepatic enzymes that convert metformin into a directly toxic acid
D) Metformin stimulates beta cell insulin secretion so strongly that hypoglycemia generates lactate
E) Metformin is filtered but fully reabsorbed in healthy kidneys, so only injured kidneys excrete enough to cause toxicity
ANSWER: A
Rationale:
Metformin is not metabolized and is cleared entirely by the kidney, so acute kidney injury causes drug accumulation; because metformin also impairs hepatic and renal lactate clearance through complex I inhibition, accumulating drug raises lactate and the risk of lactic acidosis.
Option B: Option B is incorrect because metformin is not hepatically metabolized to a lactic acid metabolite; it is eliminated unchanged.
Option C: Option C is incorrect because metformin is not converted by hepatic enzymes into a toxic acid.
Option D: Option D is incorrect because metformin is not an insulin secretagogue and does not generate lactate through hypoglycemia.
Option E: Option E is incorrect because healthy kidneys efficiently secrete and eliminate metformin rather than fully reabsorbing it.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. He is later admitted with septic shock and oliguric acute kidney injury. Laboratory studies show a high-anion-gap metabolic acidosis with a markedly elevated serum lactate. His glucose is 150 mg/dL. What is the most likely diagnosis?
A) Diabetic ketoacidosis precipitated by metformin
B) Hyperosmolar hyperglycemic state
C) Metformin-associated lactic acidosis (MALA), driven by impaired lactate clearance from accumulated metformin compounded by sepsis-related lactate production and reduced renal clearance
D) Sulfonylurea-induced hypoglycemia
E) A benign, clinically insignificant lactate elevation requiring no intervention
ANSWER: C
Rationale:
A high-anion-gap metabolic acidosis with markedly elevated lactate in a metformin-treated patient with septic shock and acute kidney injury is most consistent with metformin-associated lactic acidosis: accumulated metformin impairs lactate clearance while sepsis increases lactate production and renal injury reduces drug clearance.
Option A: Option A is incorrect because the glucose is only mildly elevated and metformin does not cause ketoacidosis.
Option B: Option B is incorrect because the glucose is not in the markedly elevated range of hyperosmolar hyperglycemic state, and that state does not explain the lactic acidosis.
Option D: Option D is incorrect because metformin does not cause hypoglycemia and the glucose here is not low.
Option E: Option E is incorrect because a markedly elevated lactate with acidosis in this setting is not benign and requires urgent intervention.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. His acidosis is severe and his renal function is poor. What is the most appropriate management of his metformin-associated lactic acidosis?
A) Continue metformin and simply add an insulin infusion to control glucose
B) Stop metformin, provide aggressive supportive care, and initiate hemodialysis, which both removes the drug and helps correct the acidosis
C) Administer high-dose intravenous dextrose, since the primary problem is hypoglycemia
D) Give oral activated charcoal as the definitive treatment for circulating metformin
E) Withhold all intervention and monitor, since lactic acidosis in sepsis resolves spontaneously
ANSWER: B
Rationale:
Severe metformin-associated lactic acidosis with poor renal function is managed by stopping metformin, providing aggressive supportive care, and initiating hemodialysis, which removes the drug and helps correct the metabolic acidosis.
Option A: Option A is incorrect because continuing metformin perpetuates the accumulation, and the primary problem is lactic acidosis, not glucose control.
Option C: Option C is incorrect because the patient is not hypoglycemic; dextrose does not address the acidosis.
Option D: Option D is incorrect because activated charcoal is not the definitive treatment for circulating metformin and does not clear drug already absorbed and distributed.
Option E: Option E is incorrect because severe lactic acidosis with renal failure requires active intervention rather than observation.
9. [CASE 3 — QUESTION 1]
A 59-year-old man with T2DM works irregular shifts and eats at unpredictable times. He has had episodes of mild hypoglycemia on a once-daily sulfonylurea taken on a fixed schedule. The team considers repaglinide. Why does repaglinide's dosing design suit his irregular meal pattern?
A) Repaglinide is taken once daily on a fixed schedule, like the sulfonylurea, but is simply more potent
B) Repaglinide is dosed at bedtime to suppress overnight hepatic glucose output regardless of meals
C) Repaglinide has such a long duration of action that meal timing becomes irrelevant
D) Repaglinide is dosed before each meal and the dose is omitted when a meal is skipped, providing short-acting prandial coverage matched to when he actually eats
E) Repaglinide is dosed only when fasting glucose is elevated, independent of meals
ANSWER: D
Rationale:
Repaglinide is a short-acting prandial secretagogue dosed before each meal, and the dose is omitted when a meal is skipped, so insulin secretion is matched to actual food intake; this dose-per-meal design suits an irregular eating schedule and reduces the interprandial hypoglycemia seen with fixed-schedule sulfonylureas.
Option A: Option A is incorrect because repaglinide is not a once-daily fixed-schedule drug; its meal-by-meal dosing is the relevant feature.
Option B: Option B is incorrect because repaglinide is a prandial agent, not a bedtime suppressor of hepatic glucose output.
Option C: Option C is incorrect because repaglinide is short-acting, so meal timing is precisely what governs dosing.
Option E: Option E is incorrect because repaglinide is dosed by meal, not by fasting glucose level.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. He also has stage 3 CKD. Which property of repaglinide makes it relatively well suited to use in renal impairment?
A) It is eliminated predominantly by hepatic metabolism and biliary excretion, with less than 10 percent renal excretion of unchanged drug, so it does not accumulate as a direct result of renal impairment
B) It is excreted unchanged by the kidney, allowing precise titration against eGFR
C) It is removed entirely by hemodialysis, making it safe at any level of renal function
D) It is not metabolized and is eliminated through exhalation, bypassing renal and hepatic routes
E) It is so highly protein-bound that it is never filtered by the glomerulus regardless of renal function
ANSWER: A
Rationale:
Repaglinide is metabolized by CYP3A4 and CYP2C8 to inactive metabolites eliminated predominantly in bile and feces, with less than 10 percent renal excretion of unchanged drug; because elimination is predominantly hepatic and biliary, it does not accumulate as a direct consequence of renal impairment.
Option B: Option B is incorrect because repaglinide is not excreted unchanged by the kidney.
Option C: Option C is incorrect because its renal safety derives from its elimination route, not from dialytic removal.
Option D: Option D is incorrect because repaglinide is hepatically metabolized, not exhaled.
Option E: Option E is incorrect because, although repaglinide is protein-bound, its renal safety stems from hepatic and biliary elimination rather than from being unfilterable.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. He is found to have severe hypertriglyceridemia, and a colleague suggests adding gemfibrozil. Integrating repaglinide's metabolism with gemfibrozil's enzyme effect, what is the correct concern?
A) Gemfibrozil induces CYP3A4, lowering repaglinide levels and causing hyperglycemia
B) Gemfibrozil displaces repaglinide from albumin, an interaction easily managed by separating doses
C) Gemfibrozil and repaglinide do not interact, since repaglinide is not metabolized by cytochrome P450 enzymes
D) Gemfibrozil competes for renal tubular secretion, causing repaglinide to accumulate to nephrotoxic levels
E) Gemfibrozil inhibits CYP2C8, raising repaglinide exposure approximately eight-fold and producing severe hypoglycemia, making the combination contraindicated
ANSWER: E
Rationale:
Gemfibrozil potently inhibits CYP2C8, a primary enzyme for repaglinide metabolism, raising repaglinide exposure approximately eight-fold and creating a severe hypoglycemia risk, so the combination is contraindicated.
Option A: Option A inverts the effect: gemfibrozil inhibits rather than induces the relevant enzyme, raising exposure and causing hypoglycemia rather than hyperglycemia.
Option B: Option B is incorrect because the interaction is metabolic enzyme inhibition with a large exposure increase, not a protein-binding displacement solved by dose separation.
Option C: Option C is incorrect because repaglinide is metabolized by CYP3A4 and CYP2C8, so a P450 interaction is exactly what occurs.
Option D: Option D is incorrect because repaglinide is eliminated by hepatic and biliary routes with minimal renal excretion, so renal tubular competition is not the mechanism.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. His severe hypertriglyceridemia still requires treatment. What is the most appropriate course of action?
A) Add gemfibrozil at half dose and reduce repaglinide by half to balance the interaction
B) Avoid gemfibrozil and select an alternative agent such as fenofibrate, which does not carry the contraindicated CYP2C8 interaction with repaglinide
C) Continue both drugs unchanged, since the triglyceride benefit outweighs the interaction
D) Stop repaglinide and start glyburide so that gemfibrozil can be added
E) Add gemfibrozil and monitor glucose closely, since the interaction is clinically minor
ANSWER: B
Rationale:
Because gemfibrozil is contraindicated with repaglinide, the appropriate course is to avoid gemfibrozil and select an alternative such as fenofibrate, which does not carry the same CYP2C8 interaction, allowing treatment of the hypertriglyceridemia without the eight-fold exposure increase.
Option A: Option A is incorrect because dose adjustments cannot reliably offset such a large, variable exposure increase from a contraindicated combination.
Option C: Option C is incorrect because continuing a contraindicated combination exposes the patient to severe hypoglycemia.
Option D: Option D is incorrect because switching to glyburide introduces its own hypoglycemia hazards and is unnecessary when the fibrate can be changed.
Option E: Option E is incorrect because the interaction is not minor; the roughly eight-fold exposure increase makes co-administration unsafe.
13. [CASE 4 — QUESTION 1]
A 52-year-old overweight man is newly diagnosed with T2DM. His eGFR is 72 mL/min/1.73m2, liver function is normal, and he has no established cardiovascular disease. He asks which oral agent has the strongest randomized evidence for reducing mortality, not merely lowering glucose. Which agent best answers this, and on what basis?
A) Glyburide, based on the UGDP (University Group Diabetes Program) trial demonstrating a mortality benefit
B) Nateglinide, based on a dedicated outcomes trial showing reduced all-cause mortality
C) Metformin, based on the UKPDS (United Kingdom Prospective Diabetes Study) overweight subgroup, which showed reduced all-cause mortality and myocardial infarction with a sustained legacy effect on follow-up
D) Repaglinide, based on outcome data showing reduced cardiovascular death
E) Chlorpropamide, based on first-generation sulfonylurea mortality data
ANSWER: C
Rationale:
The UKPDS overweight subgroup randomized to metformin showed reduced all-cause mortality and myocardial infarction compared with conventional therapy, with a sustained legacy effect on post-trial follow-up; metformin is the oral agent with the strongest randomized mortality evidence and is the appropriate first-line choice for this patient.
Option A: Option A is incorrect because the UGDP trial raised a cardiovascular concern with tolbutamide rather than showing a sulfonylurea mortality benefit.
Option B: Option B is incorrect because nateglinide's outcome trial did not show reduced all-cause mortality.
Option D: Option D is incorrect because repaglinide lacks outcome data showing reduced cardiovascular death.
Option E: Option E is incorrect because chlorpropamide has no mortality-benefit outcome data.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. His initial HbA1c (glycated hemoglobin) returns at 9.8 percent, and he has significant financial constraints that preclude GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT-2 (sodium-glucose cotransporter-2) inhibitors. Which initial strategy is most consistent with ADA guidance?
A) Start metformin monotherapy and wait a full year before adding any second agent
B) Defer all pharmacotherapy and rely on lifestyle modification until the HbA1c falls below 8 percent
C) Start a GLP-1 receptor agonist despite the cost, since sulfonylureas are never appropriate
D) Initiate combination therapy at the outset—metformin plus a low-cost generic sulfonylurea—because an HbA1c this far above target is unlikely to reach goal on monotherapy and the sulfonylurea fits the cost constraints
E) Start a sulfonylurea alone without metformin, since metformin is ineffective at a high HbA1c
ANSWER: D
Rationale:
For a patient presenting with an HbA1c well above 9 percent, ADA guidance supports initiating combination therapy rather than monotherapy; adding a low-cost generic sulfonylurea to metformin fits the secretagogue's guideline-defined role in cost-sensitive prescribing.
Option A: Option A is incorrect because a markedly elevated HbA1c warrants early combination rather than a mandatory year of monotherapy.
Option B: Option B is incorrect because lifestyle alone is inadequate at this HbA1c and pharmacotherapy should begin promptly.
Option C: Option C is incorrect because sulfonylureas retain a defined role, especially when cost precludes other agents.
Option E: Option E is incorrect because metformin remains effective and is the backbone agent, so a sulfonylurea alone is not preferred over the combination.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. Seven years later, while still on metformin, he develops a macrocytic anemia and a worsening distal sensory neuropathy. Which metformin-related cause should be suspected, and by what mechanism?
A) Vitamin B12 (cobalamin) deficiency, because metformin interferes with the calcium-dependent ileal absorption of the vitamin B12-intrinsic factor complex
B) Folate deficiency, because metformin competitively inhibits dihydrofolate reductase
C) Iron deficiency, because metformin chelates dietary iron in the gut lumen
D) Vitamin D deficiency, because metformin accelerates hepatic catabolism of 25-hydroxyvitamin D
E) Thiamine deficiency, because metformin blocks intestinal thiamine transporters
ANSWER: A
Rationale:
Long-term metformin impairs the calcium-dependent ileal absorption of the vitamin B12-intrinsic factor complex, producing vitamin B12 deficiency that manifests as macrocytic anemia and a peripheral neuropathy capable of mimicking or worsening diabetic polyneuropathy.
Option B: Option B is incorrect because metformin does not inhibit dihydrofolate reductase; that is the mechanism of antifolate drugs.
Option C: Option C is incorrect because metformin does not cause iron deficiency by chelating dietary iron.
Option D: Option D is incorrect because metformin does not cause vitamin D deficiency through accelerated hepatic catabolism.
Option E: Option E is incorrect because thiamine transporter blockade is not the metformin mechanism.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. His vitamin B12 level is confirmed to be low. What is the most appropriate management?
A) Permanently discontinue metformin, since B12 deficiency is an absolute contraindication to its continued use
B) Ignore the laboratory result, since B12 deficiency from metformin is never clinically significant
C) Treat with iron supplementation, since the anemia must be due to iron deficiency
D) Start high-dose corticosteroids to treat the presumed autoimmune cause of the anemia
E) Supplement vitamin B12, monitor B12 levels periodically going forward, and continue metformin if it remains otherwise beneficial and tolerated
ANSWER: E
Rationale:
Metformin-associated B12 deficiency is managed by supplementing vitamin B12 and monitoring levels periodically; metformin can be continued if it remains otherwise beneficial and tolerated, since the deficiency is correctable.
Option A: Option A is incorrect because B12 deficiency is not an absolute contraindication; it is a monitorable, treatable effect.
Option B: Option B is incorrect because confirmed B12 deficiency with anemia and neuropathy is clinically significant and warrants treatment.
Option C: Option C is incorrect because the deficiency is of vitamin B12, not iron, so iron supplementation does not address the cause.
Option D: Option D is incorrect because the anemia is a correctable B12-deficiency macrocytic anemia, not an autoimmune process requiring corticosteroids.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.